YOLFTbeta
20/20 Biolabs, Inc. Common Stock

20/20 Biolabs, Inc. Common Stock

AIDX · NASDAQ · Healthcare / Medical Devices

0.2043USD+0.00 (+0.25%)

Price History

Full chart

Market Stats

Previous Close0.2038
Open0.212
Day Range0.19 – 0.212
52-Week Range0.40 – 50.00
Volume52.93K
Market Cap5.40M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.58
Dividend Yield0.00%
Beta-0.42
50-Day Avg0.5104
200-Day Avg1.53

About

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Jonathan Cohen
  • Employees4
  • Headquarters15810 Gaither Road, Gaithersburg, MD, United States, 20877, USA
  • Websitehttps://2020biolabs.com

Leadership

  • Mr. Jonathan CohenFounder, CEO, President & Director · b. 1964
  • Dr. Jiming Zhou Ph.D.Chief Operating Officer · b. 1968
  • Dr. Michael Saul Lebowitz Ph.D.Chief Scientific Officer · b. 1969
  • Mr. Alan B. BergmanChief Financial Officer · b. 1969
  • Mr. David LeesDirector of Sales
  • Mr. Ronald R. BakerChief Business Officer · b. 1951
  • Marc GordonController

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue427.00K313.21K277.05K288.30K2.33M9.62M11.06M1.42M1.75M2.05M
Growth (%)--26.65%-11.55%+4.06%+708.37%+312.88%+14.93%-87.12%+23.03%+16.71%
Cost of Revenue256.22K182.28K217.59K263.92K1.45M4.93M5.94M1.32M1.39M1.44M
Gross Profit170.78K130.93K59.45K24.38K877.17K4.69M5.12M109.14K360.31K604.54K
Gross Margin40.00%41.80%21.46%8.46%37.64%48.79%46.31%7.66%20.56%29.56%
Operating Expense2.40M1.41M1.53M2.49M2.91M2.75M3.44M6.47M6.02M3.94M
Operating Income-2.23M-1.28M-1.47M-2.47M-2.03M1.94M1.68M-6.36M-5.66M-3.33M
Operating Margin-522.44%-408.42%-532.12%-855.81%-87.13%20.18%15.18%-446.64%-323.06%-162.87%
EBITDA-2.21M-1.27M-1.44M-2.42M-1.97M2.07M1.97M-6.19M-5.53M-3.50M
EBITDA Margin-516.51%-405.03%-521.01%-840.58%-84.33%21.47%17.79%-434.89%-315.31%-171.36%
Net Income-2.23M-1.26M-1.46M-2.43M-2.02M2.07M2.19M-6.39M-5.55M-3.74M
Net Income Margin-521.79%-403.63%-528.11%-841.25%-86.75%21.53%19.77%-448.73%-316.81%-182.82%
R&D424.43K267.06K234.49K195.04K338.87K193.37K120.04K1.41M1.26M592.57K
R&D as % of Total Revenue99.40%85.27%84.64%67.65%14.54%2.01%1.09%98.94%72.01%28.97%
Interest Expense9.47K----12.93K15.69K27.91K12.65K156.21K
Interest Expense % of Total Revenue2.22%----0.13%0.14%1.96%0.72%7.64%

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.35M1.42M4.11M3.13M4.68M10.27M12.22M6.37M3.61M4.14M
Total Liabilities561.95K965.94K820.54K976.56K1.29M3.38M2.84M2.08M2.08M4.16M
Total Equity784.36K456.18K3.28M2.15M3.39M6.89M9.37M4.29M1.53M-19.23K
Cash982.23K1.04M3.27M636.02K3.47M3.35M8.81M4.09M1.78M1.03B
Total Debt----144.11K2.35M2.41M2.07M1.51M1.28B
Net Debt-982.23K-1.04M-3.27M-636.02K-3.32M-1.00M-6.39M-2.02M-270.61K258.04M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.89M-1.06M-1.31M-2.12M-2.04M-1.07M5.80M-4.63M-2.60M-1.92B
Investing Cash Flow-76.87K-27.43K-436.17K-1.66M1.46M-228.15K-462.55K-43.76K--
Financing Cash Flow1.86M1.15M3.98M1.15M3.41M1.19M112.60K-45.99K293.33K1.16B
Capital Expenditure0564.08K2.29K184.07K228.15K261.79K9.38K50
Free Cash Flow-1.89M-1.06M-1.38M-2.13M-2.22M-1.30M5.54M-4.64M-2.60M-1.92B
FCF to OCF100.00%100.00%104.87%100.11%109.03%121.24%95.49%100.20%100.00%100.00%

Earnings

Report DateFeb 25, 2026May 20, 2026Aug 19, 2026Nov 13, 2026
EPS Estimate--0.10-0.12-
EPS Actual-0.13-0.28-0.26-
Surprise--180.00%-116.67%-
Timing-After-hours--

Key Statistics & Ratios

Market Cap5.40M
Enterprise Value1.47M
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.65
Price / Book3.36
EPS-0.58
Book Value0.132
Revenue (TTM)2.04M
Gross Profit (TTM)643.09K
EBITDA-4.32M
Profit Margin-285.00%
Operating Margin-170.31%
Return on Equity-331.22%
Return on Assets-62.37%
Shares Outstanding12.77M
Shares Float10.85M
Beta-0.42
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
4.23%
Insiders
25.09%
Retail / Other
70.68%

Top Institutional Holders

  • Cresset Asset Management, LLC
    264.37K2.16%
  • Atlantic Union Bankshares Corp
    35.10K0.29%
  • Citadel Advisors Llc
    23.20K0.19%
  • XTX Topco Ltd
    10.33K0.08%
  • UBS Group AG
    8.31K0.07%
  • McDonald Partners, LLC
    2.80K0.02%
  • Mccormack Advisors International
    1.00K0.01%
  • Toth Financial Advisory Corp
    1000.00%
  • Hanson Mcclain Inc
    300.00%

Top Fund Holders

  • Fidelity Extended Market Index
    43.82K0.36%
  • Fidelity Nasdaq Composite Index
    5.32K0.04%